抑郁症治疗靶标及其药物研发进展

被引：61

作者：

冯殿伟

机构：

[1] 天津市精神卫生中心

来源：

中国医院药学杂志 | 2018年 / 38卷 / 04期

关键词：

抑郁症; 靶标; 抗抑郁药; 进展;

D O I：

10.13286/j.cnki.chinhosppharmacyj.2018.04.21

中图分类号：

R749.4 [情感性精神病];

学科分类号：

100204 [神经病学];

摘要：

抑郁症的发病机制至今仍未完全阐明。传统的抗抑郁药是基于单胺递质假说而开发的。近年来,除了单胺类外,谷氨酸系统、HPA轴等一些新的抑郁症治疗靶标逐渐成为研究热点,基于这些靶标研发的新型抗抑郁药已取得重大进展,本文就抑郁症的治疗靶标和新药研发情况作一综述,为临床治疗和开发新药提供参考。

引用

页码：443 / 449

页数：7

共 22 条

[1]

Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide [J].

Thomas, Reji ;

Cetin, Mesut ;

Baker, Glen B. ;

Dursun, Serdar M. .

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 26 (04) :329-331

[2]

The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect [J].

Pytka, Karolina ;

Dziubina, Anna ;

Mlyniec, Katarzyna ;

Dziedziczak, Agnieszka ;

Zmudzka, Elnieta ;

Furgala, Anna ;

Olczyk, Adrian ;

Sapa, Jacek ;

Filipek, Barbara .

PHARMACOLOGICAL REPORTS, 2016, 68 (02) :443-450

[3]

Vortioxetine; a novel antidepressant with multimodal activity: Review of preclinical and clinical data.[J].Connie Sanchez;Karen E. Asin;Francesc Artigas.Pharmacology and Therapeutics.2015,

[4]

Addition of an NK<sub>1</sub> receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.[J].William A. Ball;Duane B. Snavely;Richard J. Hargreaves;Armin Szegedi;Christopher Lines;Scott A. Reines.Hum. Psychopharmacol Clin Exp.2014, 6

[5]

Levomilnacipran: a newly approved drug for treatment of major depressive disorder [J].